AB&B Bio-Tech: October 2026 Monthly Return Shows Stable Share Base and Sufficient Public Float

Bulletin Express11-02

AB&B Bio-Tech (H-share code: 02627) filed its Monthly Return for the period ended 31 October 2026 on 2 November 2026, confirming that no changes occurred in either authorised or issued share capital during the month.

Authorised Share Capital • Total authorised share capital remains at 393.44 million shares with a par value of RMB 1. • This comprises 296.36 million H-shares and 97.08 million domestic shares, unchanged from the previous month.

Issued Share Capital and Treasury Position • Issued H-shares stand at 296.36 million with no treasury shares held. • Issued domestic shares total 97.08 million, also with no treasury shares. • Aggregate issued shares therefore remain 393.44 million, identical to the preceding month’s figure.

Public Float Compliance The company affirmed compliance with the Main Board’s minimum public float requirement of 25 % for its H-share class as at 31 October 2026.

Corporate Actions AB&B Bio-Tech reported no share options, warrants, convertible securities, or other arrangements to issue additional shares during the month.

The filing was signed by Joint Company Secretary Xu Jian, confirming adherence to all relevant listing rules and regulatory obligations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment